Tarantini S, Nyl-Tth , Yabluchanskiy A, Csipo T, Mukli P, Balasubramanian P, et al
Results of the SURMOUNT-5 trial (ClinicalTrials.gov Identifier: NCT05822830), which evaluated the efficacy and safety of tirzepatide (dual GIP/GLP-1 RA) compared with semaglutide (GLP-1 RA) in adults with obesity or overweight, at least one weight-related comorbidity but no T2D, are in process and expected to be presented and published in 2025
This can be challenging for people who take other morning medications, can't wait 30 minutes for breakfast, or have trouble following such a strict morning routine
They found those who were on the GLP-1 medications were less than half as likely to die within five years compared to patients who were not taking the drugs (15.5% vs
Does semaglutide need to be refrigerated